As a result of the investment, we launched two new, large capacity production lines - the first one started production in early 2016. The recipe-controlled production lines supplied with an automated process controlling system enable safer-than-prescribed operation, with lower energy consumption and lower CO2 emission. The new production lines are multi-functional, i.e. suitable for producing several material types, plus they can be quickly and flexibly switched from one product to the other.

The second stage of the investment programme was completed in March 2017, when the second production line started operation. With the most advanced and most effective technologies we would like to preserve and enhance the competitive edge of the Hungarian pharmaceutical industry - having centuries’ long traditions - against its international rivals. In addition to strengthening our traditional active agent export markets (Japan, Western Europe), we are also planning to gain new strongholds.